UMIN ID: C000000393
Registered date:01/10/2012
Entecavir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | chronic hepaittis B |
| Date of first enrollment | 2006/04/01 |
| Target sample size | 20 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Baraclude (entecavir) 1mg/day p.o. |
Outcome(s)
| Primary Outcome | HBV-DNA |
|---|---|
| Secondary Outcome | Serum ALT side effects |
Key inclusion & exclusion criteria
| Age minimum | 16years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Allergy to Lamivudine complication of chronic hepatitis coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction |
Related Information
| Primary Sponsor | Gunma Liver Study Group (GLSG) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Gunma Liver Study Group (GLSG) |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Ken Sato |
| Address | 3-39-15 Showa, Maebashi, Gunma 371-8511 Japan |
| Telephone | 027-220-8127 |
| satoken@showa.gunma-u.ac.jp | |
| Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |
| scientific contact | |
| Name | Ken Sato |
| Address | 3-39-15 Showa, Maebashi, Gunma 371-8511 Japan |
| Telephone | 027-220-8127 |
| satoken@gunma-u.ac.jp | |
| Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |